Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD

被引：0
作者：
Sonia Jaramillo
Lucian Le Cornet
Markus Kratzmann
Johannes Krisam
Martin Görner
Mathias Hänel
Christoph Röllig
Maxi Wass
Sebastian Scholl
Mark Ringhoffer
Alexander Reichart
Björn Steffen
Sabine Kayser
Jan-Henrik Mikesch
Kerstin Schaefer-Eckart
Jörg Schubert
Thomas Geer
Sonja Martin
Meinhard Kieser
Tim Sauer
Katharina Kriegsmann
Michael Hundemer
Hubert Serve
Martin Bornhäuser
Carsten Müller-Tidow
Richard F. Schlenk
机构：
[1] Heidelberg University Hospital,Department of Internal Medicine V
[2] National Center of Tumor Diseases,NCT
[3] Heidelberg University Hospital and German Cancer Research Center,Trial Center
[4] University of Heidelberg,Institute of Medical Biometry
[5] Community Hospital Bielefeld,Department of Hematology, Oncology and Palliative Medicine
[6] Hospital Chemnitz gGmbH,Department of Medicine III
[7] TU Dresden University Hospital,Department of Medicine and Polyclinic I
[8] Halle (Saale) University Hospital,Department of Medicine IV
[9] Jena University Hospital,Department of Medicine II
[10] III,Department of Medicine
[11] Hospital Karlsruhe,Department of Hematology, Oncology and Palliative Medicine
[12] Hospital Winnenden,Department of Medicine II
[13] Frankfurt University Hospital,Department of Medicine I – Hematology and Cell Therapy
[14] Leipzig University Hospital,Department of Medicine A
[15] Münster University Hospital,Department of Inner Medicine V
[16] North Hospital Nürnberg,Department of Inner Medicine II
[17] Elbland Hospital Riesa,Department of Medicine II
[18] Diaconal Hospital Schwäbisch-Hall,Department of Hematology, Oncology and Palliative Medicine
[19] Robert-Bosch Hospital,undefined
来源：
Trials | / 24卷
关键词：
Quizartinib; Relapse; Refractory; Acute myeloid leukemia; Measurable residual disease; Matched threshold crossing approach;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 95 条
[1]  
Estey EH(2020)Acute myeloid leukemia: 2021 update on risk-stratification and management Am J Hematol. 95 1368-1398
[2]  
Dombret H(2016)An update of current treatments for adult acute myeloid leukemia Blood 127 53-61
[3]  
Gardin C(2017)Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO) Ann. Hematol. 96 1993-2003
[4]  
Nagel G(2001)Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine Blood 98 548-53
[5]  
Weber D(2011)Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system J. Clin. Oncol. 29 2758-65
[6]  
Fromm E(2017)Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure Leukemia 31 1306-1313
[7]  
Stone RM(2017)Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia Leukemia 31 1217-1220
[8]  
Berg DT(2020)Impact of gemtuzumab ozogamicin on MRD and relapse risk in NPM1 mutated AML patients: results from the AMLSG 09–09 Trial Blood 136 3041-3050
[9]  
George SL(2017)Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: A meta-analysis Haematologica. 102 865-73
[10]  
Röllig C(2017)Relapsed/refractory Acute Myeloid Leukemia – Any Progress? Curr Opin Oncol. 29 467-473
12345678910